Your browser doesn't support javascript.
loading
Inhibitory effect of fasiglifam on hepatitis B virus infections through suppression of the sodium taurocholate cotransporting polypeptide.
Nio, Yasunori; Akahori, Yuichi; Okamura, Hitomi; Watashi, Koichi; Wakita, Takaji; Hijikata, Makoto.
Afiliación
  • Nio Y; Takeda Pharmaceutical Company Limited, Pharmaceutical Research Division, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa, 251-8555, Japan. Electronic address: yasunori.nio@takeda.com.
  • Akahori Y; Laboratory of Tumour Viruses, Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan; Grad. Sch. of Biostudies, Kyoto University, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan.
  • Okamura H; Laboratory of Tumour Viruses, Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan; Grad. Sch. of Biostudies, Kyoto University, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan.
  • Watashi K; Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Wakita T; Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan.
  • Hijikata M; Laboratory of Tumour Viruses, Institute for Frontier Life and Medical Sciences, Kyoto University, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan; Grad. Sch. of Biostudies, Kyoto University, 53 Kawaharacho, Shogoin, Sakyoku, Kyoto 606-8507, Japan. Electronic address: mhijikat@virus.kyoto-u.a
Biochem Biophys Res Commun ; 501(3): 820-825, 2018 06 27.
Article en En | MEDLINE | ID: mdl-29723527
Fasiglifam is a selective partial agonist of G-protein-coupled receptor 40 (GPR40), which was developed for the treatment of type 2 diabetes mellitus. However, the clinical development of fasiglifam was voluntarily terminated during phase III clinical trials due to adverse liver effects. Fasiglifam showed an inhibitory effect on sodium taurocholate cotransporting polypeptide (NTCP) in human and rat hepatocytes. Recently, NTCP was reported to be a functional receptor for human hepatitis B virus (HBV) infections. Therefore, in this study, we hypothesised that fasiglifam would be a good candidate for a novel HBV entry inhibitor, and its effects were evaluated by using NTCP-overexpressing HepG2 cells, human hepatocyte cell lines and human hepatocytes (PXB cells) obtained from PXB mice. Pre-treatment with fasiglifam at a concentration of 30 µM prior to HBV infection significantly suppressed supernatant HBV DNA levels after HBV infection in NTCP-overexpressing HepG2 cells, human hepatocyte cell lines and PXB cells. Fasiglifam did not suppress supernatant HBV DNA levels up to 50 µM in HepG2.2.15.7 cells, which are stably transfected with a complete HBV genome without HBV infection. These results indicated that fasiglifam only affect on HBV infection via NTCP inhibition. For HBV treatment of fasiglifam, further investigation including additional non clinical research in addition to the evaluation of safety and efficacy in humans would be needed in the future study.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Sulfonas / Benzofuranos / Virus de la Hepatitis B / Transportadores de Anión Orgánico Sodio-Dependiente / Simportadores / Hepatitis B Límite: Animals / Humans Idioma: En Revista: Biochem Biophys Res Commun Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Sulfonas / Benzofuranos / Virus de la Hepatitis B / Transportadores de Anión Orgánico Sodio-Dependiente / Simportadores / Hepatitis B Límite: Animals / Humans Idioma: En Revista: Biochem Biophys Res Commun Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos